Muhiddin, Er MuhammedAraz, MuratHendem, EnginEryilmaz, Melek KarakurtArtac, Mehmet2024-02-232024-02-2320231078-15521477-092Xhttps://doi.org/10.1177/10781552231154009https://hdl.handle.net/20.500.12452/14433Introduction Cyclin-dependent kinase (CDK) 4/6 inhibitors have shown a different adverse effect. In this case, persistent grade 3 hepatoxicity was observed after ribociclib. Therefore, ribociclib therapy was stopped, and then palbociclib was introduced. Transaminase levels returned to normal by switching to palbociclib therapy. Case report 71-year-old postmenopausal female patient with luminal subtypes of metastatic breast cancer treated with ribociclib. Management & outcome Grade 3 hepatotoxicity secondary to ribociclib developed. She was successfully treated with palbociclib 125 mg. Discussion In our case, palbociclib was started with a full dose, to increase treatment success. Starting with a 125 mg dose was not cause any toxicity. Nevertheless, laboratory follow-up is required in terms of neutropenia and increased transaminases.eninfo:eu-repo/semantics/closedAccessRibociclibMetastatic Breast CancerHepatotoxicityArticle29512751277367624162-s2.0-85148520987Q3WOS:00093178400000110.1177/10781552231154009